In the present study, we utilized Stevia rebaudiana L. (SRLe) extract to in situ biosynthesize nanoscale alpha hematite (α-Fe 2 O 3 ) nanoparticles (NPs) with potent antioxidant, antimicrobial, and anticancer properties. SRLe-α-Fe 2 O 3 was characterized using physiochemical analyses, including UV/Vis, FTIR, XRD, DLS, EDX, SEM, and TEM studies. Among tested solvents, CHCl 3 /MeOH (2:1 v / v ) SRL extract (least polar solvent) contained the highest EY, TPC, and antioxidant capacity of ~3.5%, ~75 mg GAE/g extract, and IC 50 = 9.87 ± 0.7 mg/mL, respectively. FTIR confirmed the engagement of coating operation to the colloidal α-Fe 2 O 3 NPs. TEM, SEM, and DLS revealed that SRLe-α-Fe 2 O 3 has a spherical shape, uniform size distribution with aggregation for an average size of ~18.34 nm, and ζ = −19.4 mV, forming a repulsive barrier that helped to improve stability. The synthesized nanoparticles displayed considerable antibacterial activity against E. coli and S. aureus bacterial growth, and exhibited superior activity against the A549 lung cancer cell lines. These findings indicate that the increased availability of bioactive substances with antioxidant properties of SRLe makes it a potentially interesting material for the preparation of biologically active compounds and green synthesis of nanoparticles.
Background: The O-antigen is one of the uropathogenic Escherichia coli (UPEC) virulence factors used as a biomarker to classify E. coli strains. Objectives: In this study, the relationship between antibiotic resistance patterns and O-serogroups was investigated in UPEC strains isolated from patients with urinary tract infections (UTIs) in southern Iraq. Methods: A total of 100 UPEC isolates from the urine specimens of patients with UTIs within the age range of 4 months to 78 years in various southern Iraqi hospitals were collected (May 2017 to January 2018) and confirmed using biochemical tests (e.g., Analytical Profile Index 20E). Antibiotic susceptibility tests were performed using the disk diffusion method according to the Clinical and Laboratory Standards Institute guidelines. The multiple polymerase chain reaction technique was applied to investigate the prevalence of O-serogroups. Results: The most frequent serogroups in the E. coli isolates were O8 (27.7%) and O25 (24.4%); however, serogroup O83 was not observed in the samples. Serogroups O75, O6, O16, and O18 had the lowest frequency (1.1%) among the examined isolates. Furthermore, 10% of the isolates did not belong to any of the examined serogroups. The phenotypic tests showed that the highest and the lowest resistance belonged to piperacillin (92%) and imipenem (5%), respectively. Serogroups O4 and O21 showed the highest drug resistance; nevertheless, serogroups O75, O18, and O1 showed the lowest drug resistance. Additionally, 94% of the isolates were resistant to three or more classes of antibiotics. Conclusions: According to the results, UPEC isolates showed high resistance to common antibiotics; however, they were sensitive to imipenem and amikacin. Serogroups O8 and O25 were the most common among UPEC isolates. Moreover, O4 and O21 showed the highest drug resistance. There was a direct relationship between antimicrobial resistance and O-serogroups in UPEC isolates.
Background and Objectives: Uropathogenic Escherichia coli (UPEC) is divided into different phylogenetic groups that differ in their antibiotic resistance patterns, serogroups and pathogenicity. This study aimed to investigate the prevalence of phylogenetic groups of UPEC isolates and their relationship with serogroups and virulence factors in patients with UTIs. Materials and Methods: Of the 412 urine samples tested a total of 150 UPEC were isolated and confirmed with PCR using 16S rRNA gene. Antibiotic resistance of the isolates was tested using disk diffusion method and the isolates were divided into phylogenetic groups by the quadruplex PCR method. The prevalence of serogroups and virulence genes were investigated using multiplex PCR. Results: 87 (58%) of the isolates belonged to phylogroup B2. Virulence genes fimH (95.3%), aer (49.3%) and serogroups O8 (22.3%), O25 (21.5%) showed the highest prevalence. The lowest drug resistance was observed against imipenem (4.6%) and meropenem (3.3%). The prevalence of multidrug-resistant and extended-spectrum beta-lactamases isolates were 60% and 61.3%, respectively. We also found a significant relationship between phylogenetic groups, serogroups and virulence factors among our isolates. Conclusion: The high abundance of phylogenetic group B2, serogroups O8 and O25, and virulence genes fimH and aer indicate their importance in the pathogenesis of UPEC in this country.
Background: Renal disease results in significant disorder of hemostasis (bleeding diathesis orhypercoagulable state).Objectives: This study is to determine the changes in some hemostasis parameters in patients withchronic renal failure and identify the effect of dialysis on these changes.Patients and Methods: seventy five patients with end stage chronic renal failure were collected fromBaghdad hospital, a full detailed history and clinical examination were performed, 50 patients were onmaintenance weekly hemodialysis, and 25 patients were without dialysis.Result: Bleeding time was significantly higher in patients with chronic renal failure who didn’t needany type of dialysis, positive D-Dimer test. In some patients, Platelet count, prothrombin time, thrombintime, fibrinogene level, activated partial thromboplastin time; all did not reach significant level betweenboth groups of patients.Conclusion: hemostatic changes are not uncommon in patients with chronic renal failure, affecting thedifferent parameter hemostasis so it should be consider in the management of these patients.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.